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Abstract
N- acetylcysteine (NAC) is an antidote to prevent acetaminophen (paracetamol- APAP)- 
induced acute liver injury (ALI). The 3- bag licensed 20.25 h standard regimen, and a 12 h 
modified regimen, are used to treat APAP overdose. This study evaluated the redox thiol 
response and APAP metabolites, in patients with a single APAP overdose treated with either 
the 20.25 h standard or 12 h modified regimen. We used liquid chromatography tandem 
mass spectrometry to quantify clinically important oxidative stress biomarkers and APAP 
metabolites in plasma samples from 45 patients who participated in a randomized controlled 
trial (SNAP trial). We investigated the time course response of plasma metabolites at pre-
dose, 12 h, and 20.25 h post- start of NAC infusion. The results showed that the 12 h modi-
fied regimen resulted in a significant elevation of plasma NAC and cysteine concentrations 
at 12 h post- infusion. We found no significant alteration in the metabolism of APAP, mi-
tochondrial, amino acids, and other thiol biomarkers with the two regimens. We examined 
APAP and purine metabolism in overdose patients who developed ALI. We showed the 
major APAP- metabolites and xanthine were significantly higher in patients with ALI. These 
biomarkers correlated well with alanine aminotransferase activity at admission. Receiver 
operating characteristic analysis showed that at admission, plasma APAP- metabolites and 
xanthine concentrations were predictive for ALI. In conclusion, a significantly higher redox 
thiol response with the modified NAC regimen at 12 h postdose suggests this regimen may 
produce greater antioxidant efficacy. At baseline, plasma APAP and purine metabolites may 
be useful biomarkers for early prediction of APAP- induced ALI.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
N- acetylcysteine (NAC) is an effective antidote used to prevent acetaminophen 
(APAP)- induced acute liver injury (ALI). The 12 h modified NAC regimen has a 
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INTRODUCTION
Acetaminophen (APAP) toxicity increases the risk of acute 
liver injury (ALI) due to excess accumulation of its reactive 
metabolite, N- acetyl- p- benzoquinone imine (NAPQI). In 
APAP overdose, hepatic glutathione (GSH) is depleted lead-
ing to oxidative stress, mitochondrial dysfunction, and cell 
injury.1 N- acetylcysteine (NAC) is an effective antioxidant 
against NAPQI- induced liver injury.2 Its antioxidant effect 
is mainly attributed to NAC bioconversion to cysteine, a pre-
cursor for hepatic GSH biosynthesis.3 The UK 20.25 h stand-
ard (now increased in duration to 21 h) and 12 h modified 
i.v. NAC protocols are two common regimens used to treat 
overdose patients in the United Kingdom.4 A previous ran-
domized controlled trial has demonstrated that the modified 
regimen (Scottish and Newcastle antiemetic pretreatment for 
paracetamol poisoning study [SNAP] regimen) produces a 
lower rate of adverse reactions associated with NAC, such as 
retching, vomiting, and anaphylactoid reactions,4 while hav-
ing similar treatment efficacy at preventing APAP- induced 
ALI.5 Reduction of adverse reactions with the modified 
regimen is achieved by slowing the initial loading dose and 
thereby reducing the mean peak NAC concentration.6 NAC 
is a potent antioxidant that increases thiol biomarkers of oxi-
dative stress.7 The aim of this study was to compare the ef-
fect of standard and modified NAC regimens on circulating 
antioxidants and thiol biomarkers in patients who had taken 
an acute APAP overdose. This exploratory study also ex-
amined the endogenous metabolism of APAP that may lead 
to the discovery of novel mechanisms underpinning APAP- 
induced ALI. We used liquid chromatography tandem mass 
spectrometry (LC- MS/MS) metabolomics to quantify plasma 
metabolite concentrations at three timepoints, in a subset of 
patients from the SNAP study.8 We investigated whether 
there was any significant difference in plasma metabolite 
concentration between the standard and modified NAC 
regimens. Finally, we examined plasma APAP metabolite 
concentrations at three timepoints and identified additional 
APAP metabolites that are predictive for ALI. Overall, this 
study suggests a greater antioxidant effect in the 12 h modi-
fied NAC regimen, and identifies exploratory biomarkers for 
ALI risk assessment.
METHODS
Study design and patient cohort
The SNAP study was approved by the Medicines and 
Healthcare Products Regulatory Agency, the Scotland A 
Research Ethics Committee, UK (ref no 10/MRE00/20; 
EudraCT number 2009- 017800- 10, ClinicalTrials.gov 
Identifier NCT01050270), to examine the frequency of 
adverse reactions associated with the modified 12 h modi-
fied NAC regimen in APAP overdose.8 This study was 
designed as 2 × 2 factorial, double- blind, randomized con-
trolled trial. The trial procedure and patient recruitment 
protocol have been published in full.4,8 The study was 
conducted in accordance with the Declaration of Helsinki 
and Good Clinical Practice guidelines. These patients 
were initially recruited between September 6, 2010, until 
December 31, 2012, from 3 sites in the United Kingdom, 
the Royal Infirmary in Edinburgh, and the Royal Victoria 
Infirmary, Newcastle, and subsequently at Aberdeen Royal 
Infirmary. Inclusion criteria were patients admitted to the 
hospital within 36 h of a single acute APAP overdose and 
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lower rate of adverse effects than the 20.25 h standard NAC regimen. However, the 
effect of NAC regimen on redox thiol and APAP metabolism have not been studied.
WHAT QUESTION DID THIS STUDY ADDRESS?
What are the effects of modified and standard NAC regimens on circulating thiol 
biomarkers and APAP metabolites?
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
Patients who received 12 h modified NAC treatment have significantly higher circu-
lating cysteine concentration at 12 h postinfusion than those who received 20.25 h 
standard NAC regimen. At baseline, plasma APAP and purine metabolites were sig-
nificantly higher in patients who developed ALI.
HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR 
TRANSLATIONAL SCIENCE?
This study suggests the 12 h modified NAC regimen provides greater antioxidant pro-
tection to APAP overdose patients in this time frame allowing further NAC therapy to 
be targeted earlier to patients at risk. At baseline, plasma APAP and purine metabo-
lites are predictive biomarkers for APAP- induced ALI.
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received NAC treatment according to standard UK guide-
lines. Exclusion criteria were patients who were unable to 
consent or not suitable for participation. Full written in-
formed consent was obtained from each patient prior to 
participation in the trial, conformed with study protocol 
approved by the UK Medicines and Healthcare products 
Regulatory Agency and the Scotland A Research Ethics 
Committee, UK (ref. no. 10/MRE00/20).8 All patients were 
randomized, with concealed allocation, into four parallel 
treatment groups: ondansetron pretreatment and the shorter 
NAC regimen (ondansetron- modified); ondansetron and 
the standard schedule (ondansetron- standard); placebo and 
the shorter acetylcysteine protocol (placebo- modified); 
and placebo and the standard regimen (placebo- standard). 
Treatment procedures were assigned to patients and 
their baseline and clinical characteristics were collected 
(Table  1). All adverse events presented during the treat-
ment, any use and timing of rescue drug, clinical outcome, 
and survival data were documented by clinic staff in elec-
tronic case report form (CRF). Three blood samples were 
collected in EDTA tubes, from each randomized group at 
baseline (predose), 12  h, and 20.25  h after starting NAC 
regimen (with the predose blood samples were collected 
immediately before ondansetron pretreatment or placebo). 
Plasma samples were extracted and stored at −80°C until 
further analysis. This study analyzed samples taken in the 
setting of an acute medical emergency. A strength of this 
study was that the samples were collected soon after pres-
entation to the hospital. This means that it was impossible 
to fast the patient. The timing of the patient’s last meal 
was, unfortunately, not recorded within the SNAP trial. 
Our study was performed in a subset number (N = 45) of 
the SNAP cohort in whom were randomized to either 12 h 
modified NAC (n = 26) or 20.25 h standard NAC (n = 19) 
regimen (Figure S1).
The primary outcome of the study was progression to 
ALI after acute paracetamol overdose. ALI is defined as an 
increased serum alanine aminotransferase (ALT) of 50% or 
more (ALT rise ≥50%) at 20.25 h compared with the hospital 
admission value. As a result, we identified a total number of 
4 patients who developed ALI, 3 patients received the 12 h 
modified NAC, and 1 patient received the 20.25 h standard 
NAC regimen.
Data collection and blood sample
Baseline demographics and clinical characteristics were col-
lected at the time of recruitment and are presented in Table 1. 
Adverse reactions and treatment information related to the study 
were collected during the treatment phase via self- assessment 
and as questionnaires done by the patient and recorded on the 
CRF by trained clinical or research staff. Blood samples were 
collected by clinical staff before and after initiation of NAC 
treatment, at baseline, at 12 h, and at 20.25 h timepoints. Blood 
samples were analyzed for paracetamol concentration, full 
blood count, urea, creatinine, electrolytes, and liver function 
tests, as previously described.8 The data reported here are from 
patients in whom rapid processing and freezing of samples was 
possible, in order that the metabolites would be stable. These 
were 45 of the trial patients recruited in Edinburgh.
Chemicals and reagents, sample 
preparation, and LC- MS/MS analysis
Chemicals and reagents, sample preparation, and LC- MS/MS 
analytical procedure were described in Supplementary Text.
Statistical analysis
Numerical data are presented as mean ± SD, or median and 
interquartile range. Categorical data are presented as fre-
quency and percentage (n [%]), except for receiver operating 
characteristic (ROC) data where 95% confidence intervals 
(CIs) are presented. The final quantitative metabolomics data 
were normalized by signal drift and batch corrected using a 
custom script. Metabolomics data were log- transformed to 
adjust for normality distribution. Pairwise statistic compared 
means of all metabolite concentrations between the two regi-
mens was performed by nonparametric Mann– Whitney U 
test. Multiple groups comparison was performed by nonpara-
metric Kruskal– Wallis test with Dunn- Bonferroni post hoc 
adjustment. All statistical analyses were performed by SPSS 
version 24.0 (SPSS Inc.).
RESULTS
Effect of NAC regimen on plasma cysteine and 
cystine concentrations
We analyzed the plasma concentration of various oxidative 
stress biomarkers in serum samples from patients treated 
with NAC following acute APAP overdose. The details of 
the redox effects of NAC administration, assessed at base-
line (before NAC started but after APAP ingestion), 12  h, 
and 20.25  h postadministration, together with the concen-
trations of APAP, NAC and its metabolites (cysteine and 
cystine), amino acids, and other established oxidative stress 
biomarkers from purine, ergothioneine, acyl carnitine, and 
F2- isoprostane pathways are shown for the standard three- 
bag regimen (Table  2) and the modified NAC regimens 
(Table  3). We also compared the timepoint effect of each 
regimen on the biomarkers (Table S1).
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T A B L E  2  Concentration of metabolites in blood samples from 19 paracetamol overdose patients collected at predose, 12 h, and 20.25 h 
following standard NAC regimen
Metabolite
Standard regimen (n = 19) p value







APAP clinical 132.61 ± 72.89 5.75 ± 1.35 4.54 ± 1.12 <0.0001 <0.0001 0.044
APAP LC- MS/MS 146.86 ± 97.04 3.30 ± 2.46 1.49 ± 1.48 <0.0001*** <0.0001*** 0.032*
APAP- sulfate 62.30 ± 26.45 18.18 ± 12.45 6.31 ± 4.31 <0.0001*** <0.0001*** 0.002**
APAP- glucuronide 252.25 ± 126.23 28.15 ± 19.13 10.04 ± 7.08 <0.0001*** <0.0001*** 0.007*
APAP- cysteine 1.19 ± 0.36 0.89 ± 0.13 0.77 ± 0.03 0.009* <0.0001*** 0.069
APAP- glutathione 0.41 ± 0.11 0.34 ± 0.18 0.25 ± 0.23 0.325 0.033* 0.151
APAP- NAC 1.09 ± 0.48 0.35 ± 0.19 0.15 ± 0.04 <0.0001*** <0.0001*** 0.001**
N- acetylcysteine 0.00 ± 0.00 9.88 ± 2.83 9.13 ± 1.64 <0.0001*** <0.0001*** 0.754
Cysteine (Cys) 42.20 ± 11.03 164.91 ± 116.50 131.95 ± 68.19 <0.0001*** <0.0001*** <0.0001***
Cystine (CySS) 27.55 ± 5.88 22.76 ± 1.32 24.33 ± 3.18 0.001** 0.049* 0.154
Cys/CySS ratio 1.55 ± 0.42 7.26 ± 5.33 5.44 ± 2.83 <0.0001*** <0.0001*** 0.639
Methionine 7.79 ± 4.56 8.27 ± 4.57 11.10 ± 4.50 0.988 0.042 0.049
Betaine 6.72 ± 5.13 6.63 ± 3.43 7.65 ± 5.05 0.693 0.474 0.782
Choline 3.75 ± 2.10 4.04 ± 4.02 4.03 ± 2.04 0.422 0.630 0.175
Oxoproline 26.38 ± 20.15 25.16 ± 22.24 22.91 ± 17.76 0.651 0.759 0.965
Cystathione 6.38 ± 0.01 6.40 ± 0.04 6.41 ± 0.04 0.318 0.159 0.841
Taurine 30.71 ± 7.53 33.54 ± 11.80 39.38 ± 13.69 0.669 0.044 0.101
S- adenosyl- homocysteine 11.48 ± 2.21 12.33 ± 5.29 14.56 ± 8.34 0.812 0.606 0.480
Hypoxanthine 171.97 ± 104.00 146.86 ± 156.73 113.98 ± 144.49 0.117 0.111 0.833
Xanthine 1.82 ± 1.50 2.08 ± 3.14 2.91 ± 7.87 0.586 0.264 0.976
Uric acid 271.48 ± 76.45 211.12 ± 47.43 266.80 ± 102.30 0.014 0.404 0.190
Allantoin 0.26 ± 0.15 0.31 ± 0.22 0.24 ± 0.16 0.845 1.000 0.695
Histidine 80.96 ± 18.24 94.39 ± 21.34 94.07 ± 16.75 0.052 0.028* 0.919
Hercynine 38.47 ± 13.06 47.01 ± 15.95 39.59 ± 14.91 0.113 1.000 0.243
S- Methyl Ergothionine 23.22 ± 10.40 23.75 ± 15.71 29.49 ± 22.22 0.693 0.672 0.457
Ergothionine 1.43 ± 0.46 1.54 ± 0.48 1.85 ± 1.15 0.328 0.191 0.738
Isovalerylcarnitine 0.02 ± 0.02 0.02 ± 0.01 0.02 ± 0.01 0.060 0.133 0.421
Propionylcarnitine 0.18 ± 0.09 0.24 ± 0.09 0.24 ± 0.08 0.040* 0.014* 0.872
Butyrylcarnitine 0.04 ± 0.04 0.11 ± 0.16 0.11 ± 0.17 0.002** 0.012* 0.511
F2- isoprostane, pg/ml 7.89 ± 4.95 5.62 ± 2.78 6.62 ± 4.20 0.134 0.399 0.524
Phenlyalanine 55.64 ± 23.17 81.83 ± 23.63 79.45 ± 32.64 0.003** 0.011* 0.965
Proline 409.10 ± 178.34 410.48 ± 184.31 471.28 ± 200.46 0.737 0.287 0.249
Tyrosin 49.63 ± 28.58 52.77 ± 14.47 57.53 ± 25.31 0.405 0.343 0.474
Arginine 60.29 ± 33.89 66.79 ± 22.52 74.26 ± 29.20 0.487 0.048* 0.138
Glutamic acid 47.92 ± 17.93 69.49 ± 25.60 66.23 ± 22.84 0.010* 0.013* 0.693
Leucine 226.13 ± 173.03 167.04 ± 77.29 192.26 ± 141.85 0.609 0.609 0.827
Serine 111.70 ± 134.20 150.03 ± 98.80 152.46 ± 88.09 0.013* 0.007* 0.737
Isoleucine 73.76 ± 22.62 67.60 ± 17.59 65.23 ± 21.98 0.194 0.088 0.474
Threonine 88.50 ± 63.76 73.34 ± 41.02 135.11 ± 125.02 0.672 0.300 0.133
Glutamine 39.29 ± 15.55 35.82 ± 12.21 50.69 ± 32.69 0.671 0.136 0.064
Pyridoxine 12.23 ± 0.004 12.23 ± 0.008 12.24 ± 0.02 0.301 0.693 0.215
Pyridoxamine 34.82 ± 16.30 44.92 ± 31.63 38.64 ± 20.92 0.457 0.343 0.895
Note: Data are presented as mean ± SD and metabolite concentrations (μM). Multiple comparison between the timepoint was performed by Kruskal– Wallis tests with 
Dunn– Bonferroni post hoc.
Abbreviations: APAP, acetaminophen; LC- MS/MS, liquid chromatography tandem mass spectrometry; NAC, N- acetylcysteine.
*p < 0.05, **p < 0.005, ***p < 0.0001. 
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T A B L E  3  Concentration of metabolites in blood samples from 26 paracetamol overdose patients collected at predose, 12 h, and 20.25 h 
following modified NAC regimen
Metabolite
Modified regimen p value
Predose 







APAP clinical 127.54 ± 69.96 8.68 ± 6.04 8.52 ± 14.88 <0.0001*** <0.0001*** 0.381
APAP LC- MS/MS 129.93 ± 93.77 7.35 ± 8.55 2.32 ± 4.15 <0.0001*** <0.0001*** 0.153
APAP- sulfate 72.84 ± 51.21 33.82 ± 34.95 9.34 ± 12.29 <0.0001*** <0.0001*** 0.001**
APAP- glucuronide 277.02 ± 168.28 52.96 ± 69.78 14.35 ± 19.88 <0.0001*** <0.0001*** 0.002**
APAP- cysteine 1.40 ± 0.65 1.06 ± 0.52 0.81 ± 0.14 0.014* <0.0001*** 0.001**
APAP- glutathione 0.38 ± 0.15 0.30 ± 0.20 0.30 ± 0.21 0.487 0.113 0.148
APAP- NAC 1.40 ± 0.86 0.54 ± 0.80 0.18 ± 0.08 <0.0001*** <0.0001*** 0.026*
NAC 0.00 ± 0.00 20.99 ± 14.14 6.72 ± 0.71 <0.0001*** <0.0001*** <0.0001***
Cysteine (Cys) 47.27 ± 10.96 332.29 ± 358.57 51.43 ± 19.50 <0.0001*** <0.0001*** 0.754
Cystine (CySS) 28.82 ± 4.04 25.68 ± 4.16 26.49 ± 5.82 0.004** 0.008* 0.830
Cys/CySS ratio 1.67 ± 0.45 12.54 ± 11.03 1.97 ± 0.71 <0.0001*** 0.188 <0.0001***
Methionine 8.75 ± 4.83 7.91 ± 3.75 9.74 ± 4.90 0.660 0.453 0.257
Betaine 6.44 ± 3.25 9.62 ± 7.45 7.44 ± 2.84 0.122 0.133 0.880
Choline 3.13 ± 1.84 3.21 ± 2.21 3.14 ± 1.81 0.869 0.985 0.869
Oxoproline 29.85 ± 33.41 35.78 ± 53.93 19.94 ± 16.55 0.812 0.096 0.124
Cystathione 6.40 ± 0.05 6.42 ± 0.08 6.40 ± 0.05 0.430 0.639 0.275
Taurine 35.74 ± 10.84 32.82 ± 11.88 33.91 ± 11.18 0.148 0.370 0.583
S- Adenosyl Homocysteine 13.09 ± 4.58 12.44 ± 5.73 13.55 ± 7.08 0.393 0.865 0.411
Hypoxanthine 208.77 ± 293.28 150.06 ± 143.51 178.68 ± 212.71 0.679 0.851 0.880
Xanthine 3.46 ± 7.23 6.18 ± 18.96 3.67 ± 8.15 0.443 0.534 0.910
Uric acid 290.71 ± 88.70 265.07 ± 73.05 273.33 ± 74.79 0.368 0.221 0.678
Allantoin 0.34 ± 0.29 0.45 ± 0.73 0.31 ± 0.20 0.342 0.464 0.572
Histidine 81.00 ± 20.62 91.86 ± 26.89 80.96 ± 21.12 0.050 1.000 0.065
Hercynine 40.49 ± 16.59 40.43 ± 17.57 40.51 ± 22.25 0.733 0.639 0.536
S- Methyl Ergothionine 32.98 ± 17.19 34.08 ± 26.39 34.59 ± 21.17 0.558 0.985 0.570
Ergothionine 1.89 ± 0.84 1.76 ± 0.74 2.00 ± 0.96 0.583 0.728 0.421
Isovalerylcarnitine 0.01 ± 0.01 0.02 ± 0.02 0.02 ± 0.01 0.158 0.178 0.442
Propionylcarnitine 0.22 ± 0.17 0.28 ± 0.20 0.25 ± 0.10 0.023* 0.014* 0.964
Butyrylcarnitine 0.06 ± 0.07 0.10 ± 0.04 0.07 ± 0.03 <0.0001*** 0.002** 0.008*
F2- isoprostane, pg/ml 6.10 ± 2.72 5.02 ± 2.21 5.92 ± 3.59 0.271 1.000 0.522
Phenlyalanine 67.44 ± 29.86 70.72 ± 24.64 74.73 ± 27.87 0.421 0.314 0.728
Proline 379.70 ± 158.42 405.59 ± 216.31 345.51 ± 106.50 0.798 0.742 0.546
Tyrosine 48.30 ± 18.43 54.74 ± 57.56 48.17 ± 18.52 0.742 0.855 0.784
Arginine 66.17 ± 22.88 58.92 ± 30.34 69.42 ± 22.65 0.377 0.589 0.168
Glutamic acid 72.64 ± 54.45 75.43 ± 43.61 79.66 ± 62.54 0.400 0.855 0.400
Leucine 231.73 ± 413.17 123.63 ± 59.47 180.12 ± 168.43 0.170 0.884 0.170
Serine 82.98 ± 41.24 120.36 ± 87.17 108.85 ± 66.66 0.095 0.093 0.821
Isoleucine 68.87 ± 24.43 57.79 ± 20.59 64.37 ± 19.99 0.052 0.546 0.120
Threonine 94.56 ± 92.81 111.86 ± 68.13 104.36 ± 108.73 0.116 0.608 0.220
Glutamine 38.79 ± 20.11 35.36 ± 18.32 38.77 ± 14.13 0.170 0.913 0.107
Pyridoxine 12.24 ± 0.01 12.24 ± 0.04 12.23 ± 0.01 0.280 0.101 0.380
Pyridoxamine 35.72 ± 10.90 36.93 ± 22.42 36.48 ± 21.88 0.241 0.241 0.770
Note: Data are presented as mean ± SD and metabolite concentrations (μM). Multiple comparison between timepoint was performed by Kruskal– Wallis tests with 
Dunn– Bonferroni post hoc.
Abbreviations: APAP, acetaminophen; LC- MS/MS, liquid chromatography tandem mass spectrometry; NAC, N- acetylcysteine.
*p < 0.05, **p < 0.005, ***p < 0.0001. 
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Effect 12 h after starting NAC
Both regimens delivered an NAC dose of 300 mg/kg but the 
rate of drug delivery was different. In the SNAP trial, NAC 
was stopped in all patients at the end of the modified NAC 
regimen, however, in clinical practice, NAC would continue 
in those with evidence of liver injury or detectable APAP lev-
els. Blood was drawn at the end of the modified NAC regimen 
(12 h after starting) and compared with the same timepoint in 
the three- bag regimen. The serum NAC concentration was 
higher in the patients treated with the modified regimen than 
the standard regimen (standard regimen 9.88 ± 2.83 µM vs. 
modified regimen 20.99  ±  14.14, p  <  0.001). The stand-
ard NAC regimen resulted in 3.9- fold (42.20  ±  11.03 vs. 
164.91 ± 116.50 µM, p < 0.0001) increase in plasma cysteine 
at the 12 h timepoint. However, there was a higher plasma 
cysteine concentration in the modified regimen with seven-
fold (47.27 ± 10.96 vs. 332.29 ± 358.57 µM, p < 0.0001) 
increase from baseline at the 12 h timepoint (12 h: standard; 
164.91 ± 116.50, modified; 332.29 ± 358.57 µM, p =0.02). 
Because NAC can reduce cystine (the oxidized, dimeric 
form of cysteine) to cysteine in the plasma, we measured 
the plasma cystine concentration. At 12 h, the reduction in 
cystine after NAC was significant and of similar magnitudes 
with the two regimens.
Effect 20.25 h after starting NAC
This timepoint was at the end of the standard NAC regi-
men and 8.25 h after stopping the modified NAC regimen. 
At this time, NAC was higher with the standard regimen 
but it remained elevated in the modified regimen treated pa-
tients (standard 9.13 ± 1.64 vs. modified 6.72 ± 0.71 µM, 
p < 0.001). Cysteine was elevated compared with baseline 
in the standard treatment group but had returned to base-
line concentration after NAC was stopped in the modified 
treatment group (standard 131.95  ±  68.19 vs. modified 
51.43 ± 19.50 µM, p = 0.001). Cystine remained lower than 
the pre- NAC concentration with both regimens.
Effect of NAC regimen on plasma 
thiol biomarkers
Because APAP- induced liver injury increases oxidative 
stress in the mitochondria, elevation of plasma acylcarnitines 
can indicate early hepatocytes injury in APAP overdose.9 We 
observed elevation of plasma butyrylcarnitine and propionyl-
carnitine concentrations in standard (Table 2) and modified 
regimens (Table  3). However, plasma butyrylcarnitine and 
propionylcarnitine were not significantly different between 
the two regimens (Table  S1). In addition to alterations in 
plasma acylcarnitines, NAC administration also resulted in 
elevated levels of several amino acids (serine, glutamic acid, 
and phenylalanine), with the two timepoints being signifi-
cantly different to pretreatment in the standard regimen, but 
not in the modified regimen. However, plasma concentration 
of other thiol biomarkers from purine, allantoin, ergothio-
neine, and F2- isoprostane pathways were not significantly 
different in the standard (Table 2) and the modified regimens 
(Table 3).
Effect of NAC regimen on APAP metabolites
Given the differences in NAC and cysteine concentrations 
between the two regimens we optimized LC- MS/MS to ex-
amine plasma APAP parent drug and metabolite concentra-
tions to explore if there was a treatment regimen effect on 
drug metabolism. The concentrations of APAP and its five 
major metabolites at predose, 12 h, and 20.25 h postinitia-
tion of NAC are presented in the standard (Table 2) and the 
modified regimens (Table 3). There was no difference in the 
concentrations of the metabolites between the two regimens 
predose, at 12 h, or 20.25 h.
APAP metabolites and ALI
It has been reported that elevated plasma APAP- cysteine 
predicts ALI after APAP overdose.10 In agreement with pre-
vious findings, we found that the plasma concentration of 
APAP- cysteine (2.07 ± 0.80 vs. 1.20 ± 0.46 µM, p = 0.002) 
and the ratio of APAP- cysteine/APAP (%) (4.89 ± 2.56 vs. 
1.09  ±  0.77, p  <  0.0001; Table  4) was higher in patients 
who developed ALI than those without (no ALI). Plasma 
ALT (189.75 ± 167.78 vs. 22.43 ± 15.38 U/L, p < 0.0001) 
and APAP- cysteine/APAP (log- transformed) at baseline 
were significantly higher in patients who developed ALI 
(4.89 ± 2.56 vs. 1.09 ± 0.77, p < 0.0001; Table 4), compared 
with those who did not developed ALI (Figure 1a,b). The area 
under curve (AUC0– 20.25 h) of APAP- cysteine/APAP fraction 
was significantly higher in patients with ALI compared with 
without ALI (Figure 1c). The AUC0– 20.25 h of plasma APAP- 
cysteine/APAP fraction was positively correlated with plasma 
ALT at admission (Figure  1d). We used ROC analysis to 
evaluate the predictive values of the five APAP- metabolites 
measured at baseline for ALI (Table  5). We demonstrated 
the APAP metabolites derived from CYP- mediated pathway 
were predictive for ALI: APAP- cysteine (APAP- cysteine/
APAP % with ROC- AUC of 0.85 [95% CI  =  0.71– 0.99, 
p = 0.002]), APAP- glutathione (APAP- glutathione/APAP % 
with ROC- AUC of 0.90 [95% CI = 0.74– 1.00, p = 0.009]), 
and APAP- NAC (APAP- NAC/APAP % with ROC- AUC of 
0.80 [95% CI =0.64– 0.95, p = 0.018]). Non- CYP- mediated 
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T A B L E  4  Baseline levels of clinical variables, APAP, and purine metabolites categorized by patients with ALI (n = 4) or no ALI (n = 40)
Baseline level ALT rise < 50% ALT rise > 50% p value
Clinical variables
ALT (U/L) at admission 22.43 ± 15.38 189.75 ± 167.78 <0.0001***
APAP clinical (at admission) 141.21 ± 66.06 50.00 ± 38.09 0.012*
INR 0.97 ± 0.08 1.13 ± 0.05 0.004*
Bilirubin 9.50 ± 9.62 18.50 ± 5.97 0.075
AlkPhos 80.55 ± 59.88 67.25 ± 14.03 0.663
GGT 60.38 ± 104.49 21.75 ± 16.27 0.469
Urea 4.04 ± 2.29 4.67 ± 1.27 0.591
Creatinine 68.73 ± 12.76 86.00 ± 23.05 0.021*
Hb, g/L 140.87 ± 16.01 135.00 ± 15.13 0.543
MCV 91.79 ± 4.92 93.00 ± 7.00 0.693
WBC 8.27 ± 2.36 9.56 ± 4.64 0.398
Ingestion- time to NAC treatment 0.006*
Number of patients <8 h ingestion to starting NAC 28 (70) 0 (0)
Number of patients >8 h ingestion to starting NAC 12 (30) 4 (100)
APAP overdose 0.497
<16 g 23 (57.50) 3 (75.00)
>16 g 17 (42.50) 1 (25.00)
APAP metabolite
APAP LC- MS/MS 143.71 + 95.19 61.50 + 62.41 0.079
APAP- cysteine 1.20 + 0.46 2.07 + 0.80 0.002**
APAP- glucuronide 265.90 + 154.46 243.98 + 187.40 0.791
APAP- glutathione 0.38 + 0.15 0.45 + 0.01 0.358
APAP- sulfate 69.00 + 45.26 46.24 + 21.96 0.330
APAP- mercapturate 1.27 + 0.78 1.04 + 0.56 0.567
APAP- sulfate/APAP 106.65 + 224.23 125.73 + 106.41 0.868
APAP- glucuronide/APAP 320.68 + 484.97 472.13 + 163.00 0.018*
APAP- cysteine/APAP 1.09 + 0.77 4.89 + 2.56 <0.0001***
APAP- glutathione/APAP 0.34 + 0.34 1.22 + 0.66 0.009*
Purine metabolite
Hypoxanthine 161.94 + 196.53 230.74 + 122.03 0.027*
Xanthine 1.94 + 3.57 25.50 + 29.42 <0.0001***
Uric acid 264.11 + 84.25 315.36 + 56.35 0.023*
Allantoin 0.32 + 0.38 0.39 + 0.24 0.151
Hypoxanthine/total 31.00 + 19.00 38.00 + 11.00 0.160
Xanthine/total 0.40 + 1.00 4.40 + 5.00 <0.0001***
Uric acid/total 68.80 + 19.50 13.00 + 8.00 0.041*
Allantoin/total 0.10 + 0.10 0.10 + 0.10 0.822
Note: ALI is defined as ALT rise >50% at 20.25 h compared with the hospital admission value. Data are presented as mean ± SD and frequency n (%). All 
measurements were assessed at baseline. Plasma purine metabolite is expressed as absolute concentration (μM) and as ratio of each metabolite formed relative to total 
purine metabolites (ratio (%). Plasma APAP metabolites is expressed as concentrations (μM) and as ratio of each APAP metabolite formed relative to APAP drug 
(ratio (%). Pairwise comparison was performed by Mann– Whitney U test.
Abbreviations: ALI, acute liver injury; ALT, alanine aminotransferase; APAP, acetaminophen; GGT, gamma glutamyltransferase; INR, International Normalized 
Ratio; LC- MS/MS, liquid chromatography tandem mass spectrometry; NAC, N- acetylcysteine, WBC, white blood cell.
*p < 0.05, **p < 0.005, ***p < 0.0001. 
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pathway: APAP- glucuronide (APAP- Glucuronide/APAP % 
with ROC- AUC of 0.86 [95% CI = 0.75– 0.96, p = 0.018]). 
A combination of both the APAP non- CYP/CYP metabo-
lites and xanthine in the ROC model had superior predictive 
power for ALI with ROC- AUC of 0.98 (95% CI = 0.94– 1.00, 
p < 0.0001; Table 5), compared with individual metabolites 
in predicting ALI. Collectively, our data suggest assessment 
of non- CYP/CYP- APAP and xanthine metabolites to predict 
risk of subsequent development of ALI at presentation to the 
hospital.
Purine metabolites and ALI
In humans, xanthine oxidase (XO) enzyme produces uric 
acid by breakdown of hypoxanthine to xanthine in the pu-
rine metabolism pathway. These endogenous metabolites 
and reactive oxygen species can be cytotoxic. APAP can 
trigger XO to produce exogenous cytotoxic metabolites.11 
We examined purine metabolites in the SNAP cohort, 
and found that patients with ALI had a markedly higher 
plasma xanthine concentration (no- ALI: 1.94 ± 3.57, ALI: 
25.50 ± 29.42 µM, p < 0.0001), and a higher ratio of xan-
thine/total purine metabolites (0.40 ± 1.00 vs. 4.40 ± 5.00, 
p  <  0.0001; Table  4). The AUC0– 20.25  h of total purine 
metabolites (8322.49 ± 3209.30 vs. 11644.76 ± 2440.88, 
p = 0.031; Figure 2a) and of xanthine, expressed as a frac-
tion relative to total purine metabolites, xanthine/total (%) 
from time 0– 20.25 h after initiation of NAC, (0.39 ± 0.24 vs. 
3.22 ± 2.79, p = 0.0001; Figure 2b) were also significantly 
higher in patients with ALI compared with those with no 
ALI. The AUC0– 20.25 h of xanthine significantly correlated 
with ALT at admission (r = 0.497, 95% CI = 0.386– 0.705, 
p  <  0.0001; Figure  2c). The performance of each purine 
metabolite for ALI at baseline was evaluated using ROC 
analysis (Table 5). Plasma xanthine and its ratio (xanthine/
total purine metabolites [%]) predicted ALI with ROC- AUC 
of 0.90 (95% CI = 0.79– 1.00, p < 0.0001; Table 5). Taken 
together, our data suggest that plasma xanthine is elevated 
in overdose patients with ALI. There was no difference in 
xanthine concentration between the modified and standard 
NAC regimens.
F I G U R E  1  Alanine aminotransferase (ALT) and acetaminophen (APAP)- cysteine levels in patients with acute liver injury (ALI; n = 4), as 
defined by >50% ALT rise at 20.25 h, and patients without ALI (no ALI; n = 40). (a) Serum ALT level at admission in patients stratified by ALI 
(n = 4) and no ALI (n = 40). (b) Plasma APAP- cysteine level is expressed as a ratio of metabolite formed by APAP- cysteine relative to APAP drug 
(APAP- CYS/APAP) (%) at admission in ALI (n = 4) and no ALI (n = 40) patients. (c) Area under the curve (AUC) for APAP- CYS is expressed 
as a fraction of APAP- CYS (APAP- CYS/APAP) (%) from time 0 to 20.25 h (AUC0– 20.25 h) after initiation of N- acetylcysteine (NAC) in ALI 
(n = 4) and no ALI (n = 40) patients. (d) Correlation between the AUC of APAP- cysteine expresses as a fraction of APAP- CYS (APAP- CYS/
APAP) (%) from time 0 to 20.25 h (AUC0– 20.25 h) after initiation of NAC and serum ALT at admission in ALI (n = 4) and no ALI (n = 40) patients. 
All measurements were log- transformed and reported by geometric means and ratios. (a– c) Box plots represent median (interquartile range) and 
whisker represents range. Pairwise comparison was performed by Mann– Whitney U test. (d) Spearman correlation was performed. *p < 0.05, 
**p < 0.005. CI, confidence interval
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DISCUSSION
This study investigated the effects of the standard and modi-
fied NAC regimens on a wide range of thiol- based antioxi-
dants and APAP metabolites. We compared the efficacy of 
identical total doses of NAC (300  mg/kg) administered by 
i.v. infusion of either 20.25  h duration (standard regimen) 
or 12  h duration (modified regimen) on total antioxidant- 
capacity, in a subgroup of patients with single APAP over-
dose (SNAP cohort).8 We evaluated phenotyping profiles of 
plasma APAP metabolism and thiol concentrations at base-
line and two timepoints after initiation of NAC. All patients 
were admitted to the hospital within 36 h of a single APAP 
overdose and received either standard or modified NAC and 
had three blood samples collected for biochemical and LC- 
MS/MS analyses. The standard regimen begins with a large 
loading dose then gradually decreasing concentrations up to 
20.25  h (150  mg/kg in 200  ml, over 15  min, 50  mg/kg in 
0.5 L, over 4 h, and 100 mg/kg in 1 L, over 16 h), whereas the 
modified regimen begins with smaller loading dose (100 mg/
kg in 200 ml, over 2 h, 200 mg/kg in 1 L, over 10 h).4 The 
modified regimen has reduced adverse reactions associated 
with NAC treatment,4 with comparable treatment effective-
ness to the standard regimen.5 In the liver, NAC is metabo-
lized to cysteine, a precursor to minimize GSH depletion due 
to APAP overdose. At present, the antioxidant potential gen-
erated by the modified and standard regimens has not been 
reported.
Standard and modified NAC regimens
Our main finding was the modified NAC regimen substantially 
enhanced cysteine/cystine redox thiol response, which would 
be expected to lead to a greater antioxidant effect within the 
first 12 h of treatment. Because NAC is a precursor of GSH, 
NAC infusion enhances the plasma concentration of cysteine 
for GSH biosynthesis. GSH is a main protein thiol molecule 
for the conjugation of NAPQI.12 Timepoint analysis showed 
the modified NAC regimen had a higher plasma cysteine con-
centration (7- fold increase at the 12  h timepoint relative to 
baseline; Table 3), compared with the standard NAC regimen 
(3.9- fold increase at the 12  h timepoint relative to baseline; 
Table 2) and markedly increased the cysteine/cystine redox po-
tential (17 mV; Table S2). In the standard regimen, the steady- 
state redox potential for cysteine (Eh  =  −110  mV) noted an 
increase (Eh = −150 mV) at 12 h, whereas the modified regi-
men (Eh = −112 mV) noted an increase to (Eh = −169 mV) 
at 12 h. A greater increase in plasma cysteine (Eh = 17 mV) 
was observed in the modified as compared with the standard 
regimen (Table  S2). In addition, we demonstrated the ex-
pected reduction in plasma cysteine at 20.25  h timepoint in 
the modified regimen (standard: 332.29 ± 358.57 µM; modi-
fied 51.43 ± 19.50 µM, p < 0.0001; Table 3) when the infu-
sion of NAC discontinued after 12 h in the modified protocol. 
However, in clinical practice, in those patients with raised par-
acetamol concentrations or liver injury after 12 h of the modi-
fied protocol, NAC would be continued and this decrease in 
plasma cysteine would, not only not occur, but based on these 
data cysteine concentrations would be expect to be higher as 
a result of further NAC. The normal human plasma concen-
tration of total cysteine/cystine (reduced and oxidized) has 
been reported to be 89.13– 107.29 µM (cited reference range)13 
and the cysteine/cystine redox potential has been reported to 
be −84.6  mV.14 The plasma cysteine/cystine concentration 
and cysteine/cystine redox potential were not significantly af-
fected by APAP administration in healthy human subjects.15,16 
T A B L E  5  Predictive accuracy of APAP and purine metabolites 
for ALI
Baseline level AUC [95% CI] p value
APAP metabolite
APAP LC- MS/MS 0.17 [0.00– 0.39] 0.031*
APAP- sulfate 0.32 [0.08– 0.55] 0.236
APAP- glucuronide 0.41 [0.10– 0.72] 0.568
APAP- cysteine 0.91 [0.81– 1.00] 0.007*
APAP- NAC 0.35 [0.08– 0.62] 0.380
APAP- glutathione 0.73 [0.48– 0.97] 0.142
APAP- sulfate/APAP 0.69 [0.46– 0.92] 0.206
APAP- glucuronide/APAP 0.86 [0.75– 0.96] 0.018*
APAP- cysteine/APAP 0.85 [0.71– 0.99] 0.002**
APAP- NAC/APAP 0.80 [0.64– 0.95] 0.018*
APAP- glutathione/APAP 0.90 [0.74– 1.00] 0.009*
Purine metabolite
Hypoxanthine 0.72 [0.59– 0.85] 0.027*
Xanthine 0.91 [0.82– 1.00] <0.0001***
Uric acid 0.73 [0.60 −0.85] 0.025*
Allantoin 0.64 [0.45– 0.83] 0.157
Hypoxanthine/total 0.64 [0.51– 0.78] 0.151
Xanthine/total 0.90 [0.79– 1.00] <0.0001***
Uric acid/total 0.35 [0.11– 0.58] 0.395
Allantoin/total 0.48 [0.26– 0.69] 0.822
Sum of APAP metabolites 
panel and xanthine/total
0.98 [0.94– 1.00] <0.0001***
Note: Receiver operating characteristic- area under the curve with 95% CI for 
APAP and purine metabolites measured at baseline (predose) shows predictive 
value of each metabolite for ALI (alanine aminotransferase rise > 50% at 
20.25 h compared with the hospital admission value). Sum of APAP Non- 
CYP/CYP metabolites panel (APAP- glucuronide/APAP + APAP- cysteine/
APAP + APAP- NAC/APAP + APAP- glutathione/APAP).
Abbreviations: ALI, acute liver injury; APAP, acetaminophen; CI, confidence 
interval; LC- MS/MS, liquid chromatography tandem mass spectrometry; NAC, 
N- acetylcysteine.
*p < 0.05, **p < 0.005, ***p < 0.0001. 
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Compared with the normal range, we observed a slight reduc-
tion in plasma concentration of total cysteine/cystine at predose 
of 69.75 ± 16.91 µM (standard NAC regimen) (Table 2) and 
76.09 + 15 µM (modified NAC regimen; Table 3), possibly a 
consequence of APAP overdose that oxidized plasma cysteine/
cystine.15 The significant increase in plasma cysteine/cystine at 
12 h and 20.25 h timepoints is likely to be a consequence of 
NAC treatment.
Effect of NAC on plasma amino acids
APAP- induced oxidative stress and GSH depletion can have 
significant impact on amino acid metabolism.16– 20 APAP ex-
posure depletes amino acid and decreases plasma amino acid 
concentrations.16,21 Amino acids, such as leucine, isoleucine, 
valine, lysine, methionine, tyrosine, and phenylalanine, have 
important anti- oxidant activity.22 Several amino acids, serine, 
methionine, glutamic acid, and cysteine are precursors for GSH 
synthesis, and any deviation from normal plasma range of 
these amino acids can be an indicator of oxidative stress.16,23– 25 
These amino acids play different roles regarding their function 
as scavengers of reactive oxygen species. In fact, cysteine is 
a main precursor for GSH, controlling rate- limiting synthesis 
via the γ- glutamyl cycle. Serine (a donor of carbon atom) and 
methionine (donor of – SH) are important molecules for endog-
enous synthesis of cysteine.26,27 Phenylalanine regulates APAP 
sulfation in which its deficiency reduces APAP metabolism via 
CYPP450- mediated and non- CYPP450- mediated pathways.28 
At present study, we showed significant differences in plasma 
concentrations of amino acids at 12 h and 20.25 h timepoints. 
Because baseline plasma concentrations of amino acids were 
not significantly affected by APAP,16,22 our result suggests the 
increase in plasma concentrations of amino acids may be a con-
sequence of NAC treatment.
APAP metabolites and ALI
In the liver, APAP parent drug is predominantly metabo-
lized to noncytotoxic conjugates: APAP- glucuronide and 
APAP- sulfate through glucuronidation and sulfation. A 
F I G U R E  2  Purine metabolites level in patients with acute liver injury (ALI) (n = 4), as defined by >50% alanine aminotransferase (ALT) 
rise at 20.25 h, and patients without ALI (no ALI; n = 40). (a) Plasma purine metabolites concentration (µM) are expressed as the total metabolites 
formed (hypoxanthine, xanthine, uric acid, and allantoin) from time 0 to 20.25 h after initiation of NAC in ALI (n = 4) and no ALI (n = 40) 
patients. (b) Area under the curve (AUC) for xanthine is expressed as a fraction of xanthine metabolite relative to total purine metabolites 
(xanthine/total) (%) from time 0 to 20.25 h after initiation of NAC (AUC0– 20.25 h) in ALI (n = 4) and no ALI (n = 40) patients. (c) Correlation 
between the AUC for xanthine expressed as a fraction of xanthine metabolite relative to total purine metabolites (xanthine/total) (%) from time 0 to 
20.25 h after initiation of NAC (AUC0– 20.25 h) and serum ALT) at admission in all patients (n = 44). All measurements were log- transformed and 
reported by geometric means and ratios. (a– b) Box plots represent median (interquartile range) and whisker represents range. Pairwise comparison 
was performed by Mann– Whitney U test. (c) Spearman correlation was performed. *p < 0.05, **p < 0.005, ***p < 0.0001. CI, confidence interval
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minor fraction of APAP is oxidized by cytochrome P450 
(CYP) enzymes to the toxic metabolite NAPQI. Excess 
NAPQI can cause liver injury, but it is eliminated by bind-
ing to GSH to form APAP- GSH, which is further con-
verted to APAP- cysteine (APAP- CYS) and APAP- NAC 
(APAP- mercapturate). NAPQI also binds cellular cysteine 
to form an APAP- cysteine protein adduct, which can be 
detected before hepatic GSH depletion or liver injury de-
velops.29 These APAP metabolites are stable in the circu-
lation for hours- to- days after a single APAP overdose.30– 32 
Therefore, assessing circulating APAP metabolites may 
predict risk of subsequent liver injury.10 In line with pre-
vious studies, APAP- CYS was able to predict the subse-
quent progression to ALI with an AUC- ROC of 0.91 (95% 
CI = 0.81– 1.00, p = 0.007; Table 5). In addition, the ROC 
analysis also revealed that APAP- GSH, APAP- NAC, and 
APAP- glucuronide could potentially predict ALI risk 
(Table  5). Therefore, our data suggest that these APAP 
metabolites could improve ALI risk prediction. Despite 
the differences in the regimens regarding the protocol for 
delivery of NAC, and NAC and cysteine concentrations, 
there was no significant difference in the APAP metabo-
lites. This may be due to only four patients having mild 
liver injury. A study of increased numbers of patients with 
toxicity would be expected to enrich these data for excess 
toxic metabolite production. Thus, although we cannot 
exclude a signal of a difference between the treatment 
groups, the lack of difference in the effect on APAP me-
tabolism is consistent with there being no difference in the 
incidence of liver injury when the modified and standard 
regimens were compared.5 Finally, the circulating concen-
tration of APAP metabolites may not faithfully reflect the 
environment inside the hepatocyte such that any differ-
ence in the redox state inside the cell is not reflected in the 
circulation, at least in the absence of hepatocyte necrosis 
resulting in membrane rupture and release of the intracel-
lular environment.
Xanthine metabolism and APAP- induced ALI
Increased serum xanthine oxidase has been associated 
with APAP- induced liver injury.33 Animal studies report 
that excess APAP and NAPQI metabolite activate purine 
oxidation, which leads to an increase in production of pu-
rine oxidants and reactive oxygen species.34,35 This change 
in purine metabolites, also demonstrated in animals with 
APAP toxicity, could potentially be a novel indicator of 
liver injury in man.36 Thus, inhibiting xanthine oxida-
tion, or the enzyme XO, is potentially a novel therapeutic 
strategy to prevent APAP- induced liver injury.37 For ex-
ample, a preclinical study showed that a high dose of XO 
inhibitor allopurinol significantly reduced oxidant stress 
and APAP- induced hepatotoxicity.37 In addition, elevation 
of serum XO has been recently reported in patients with 
liver injury.4,38 We found that xanthine was significantly 
elevated in APAP overdose patients who subsequently 
developed ALI (Table  4). These data suggest that APAP 
overdose activates XO and production of xanthine can po-
tentially induce APAP- induced hepatotoxicity, independ-
ent of CYP- mediated APAP metabolism. Collectively, both 
purine and APAP metabolites may increase levels of oxi-
dized protein thiols following overdose.
Our study has several limitations. First, we only have 
samples from two timepoints after the initiation of NAC. 
Second, the sample size is relatively small to obtain reli-
able estimates of hard clinical outcomes. Third, all pa-
tients in this study were those with single APAP overdose 
and required NAC therapy. The mean rise in ALT activity 
(predefined as at least a 50% rise in serum ALT activity at 
20.25 h in the SNAP cohort was modest),8 and there was no 
significant difference in liver injury between the modified 
and standard NAC regimens. Therefore, this study was not 
large enough to accurately describe the metabolite response 
to severe liver injury.
To conclude, we assessed oxidative stress biomarkers and 
APAP metabolites in APAP overdose patients treated with 
either standard or modified NAC regimen. We demonstrated 
that the 12 h modified NAC regimen used in the SNAP trial 
may provide greater antioxidant effects, as shown by in-
creased plasma cysteine concentration (and cysteine/cystine 
redox potential), compared to the 20.25 h standard NAC reg-
imen. Our study also revealed a novel role for purine metabo-
lism in human APAP- induced hepatotoxicity. Further clinical 
studies are required to translate these findings into clinical 
practice.
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